NEORAL for Psoriasis: Side Effects & Safety Data
Visibly Younger Skin in Weeks
Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.
There are 7 adverse event reports in the FDA FAERS database where NEORAL was used for Psoriasis.
Most Reported Side Effects for NEORAL
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Blood creatinine increased | 18 | 7.0% | 2 | 7 |
| Death | 17 | 6.6% | 17 | 1 |
| Immunosuppressant drug level increased | 14 | 5.4% | 3 | 7 |
| Renal failure | 13 | 5.0% | 3 | 7 |
| Interstitial lung disease | 11 | 4.3% | 6 | 3 |
| Kidney transplant rejection | 11 | 4.3% | 3 | 7 |
| Renal impairment | 11 | 4.3% | 1 | 3 |
| Maternal exposure during pregnancy | 10 | 3.9% | 0 | 3 |
| Oral administration complication | 9 | 3.5% | 4 | 4 |
| Pyrexia | 9 | 3.5% | 2 | 5 |
| Renal failure acute | 9 | 3.5% | 0 | 8 |
| Drug interaction | 8 | 3.1% | 1 | 6 |
| Dyspnoea | 8 | 3.1% | 4 | 7 |
| Oedema | 8 | 3.1% | 2 | 3 |
| Oedema peripheral | 8 | 3.1% | 1 | 8 |
Other Indications for NEORAL
Renal transplant (52)
Off label use (22)
Interstitial lung disease (18)
Prophylaxis against transplant rejection (14)
Product used for unknown indication (13)
Immunosuppression (12)
Nephrotic syndrome (10)
Aplastic anaemia (8)
Heart transplant (8)
Liver transplant (8)
Other Drugs Used for Psoriasis
APREMILAST (76,127)
SECUKINUMAB (58,471)
ADALIMUMAB (56,634)
RISANKIZUMAB-RZAA (40,890)
ETANERCEPT (30,483)
USTEKINUMAB (21,763)
IXEKIZUMAB (16,569)
GUSELKUMAB (11,736)
CERTOLIZUMAB PEGOL (8,179)
METHOTREXATE (6,628)